Poster Session 4

Presentation numberPS4-01-01

Multi-omics analysis of breast cancer with subtype classification

Tomomi Kon, Graduate School of Medicine, Tohoku University, Sendai, Japan

Presentation numberPS4-01-02

A Comparative Analysis of TAR and NLR in Patients with triple negative breast cancer treated with as KEYNOTE-522 trial : Distinct Predictors of Pathologic Response and Survival

Airi Han, YUWMC, Wonju, Korea, Republic of

Presentation numberPS4-01-04

Circulating MIRNA Signature Predicts Breast Cancer Metastasis: A Pilot Study for Non-Invasive Risk Stratification

Veladi Sasimouli, Sri Shankara Cancer Hospital and Research Centre, bangalore, India

Presentation numberPS4-01-05

Mitotic Circulating Tumor Cells Correlates with Poor Clinical Outcomes in Metastatic Breast Cancer Patients over a 3 Year Period

Alexis B Duffy, Creatv Microtech Inc., Monmouth Junction, NJ

Presentation numberPS4-01-06

Genomic alterations in young adults compared to average-onset patients with breast cancer

Nerea Lopetegui-Lia, The Ohio State University, Columbus, OH

Presentation numberPS4-01-07

Prospective Validation of HER2DX in Early HER2+ Breast Cancer: Operational Feasibility of Centralized Genomic Screening in the DEFINITIVE Trial. Real-Time Insights from the First 80 Screened Patients

Marta Gonzalez Rodriguez, Hospital Clínic Barcelona, Barcelona, Spain

Presentation numberPS4-01-08

Ex vivo cytokine profiling of live triple negative breast cancer patient specimens from core needle biopsies illustrates proof of concept to assess tumor response to immune checkpoint inhibition

Pooja P Advani, Mayo Clinic, Jacksonville, FL

Presentation numberPS4-01-09

How does proteomics-based prognostic testing compare to genomic tests and online clinical risk prediction tools in early breast cancer patients?

Manjiri Bakre, OncoStem Diagnostics Pvt Ltd, Bangalore, India

Presentation numberPS4-01-10

Characterizing CCR7 Gene Amplification and Protein Expression in Inflammatory and non-inflammatory Breast Cancer

Surbhi Shivhare, The University of Texas MD Anderson Cancer Center, Houston, TX

Presentation numberPS4-01-11

Exploration of racial differences in variants of uncertain significance (VUS), ESR1 and PIK3CA mutation frequency, matched therapy use, and outcomes in metastatic breast cancer (mBC)

Andrew A Davis, Washington University in St. Louis, St. Louis, MO

Presentation numberPS4-01-12

Androgen receptor and FOXA1 in breast cancer: Prognostic insights from a treatment-naïve historical cohort

Yuka Inoue, Cancer Institute Hospital of JFCR, Tokyo, Japan

Presentation numberPS4-01-13

Comparative efficacy of antibody drug conjugates (ADCs) in male versus female breast cancer across the spectrum of HER2 expression

Dario Trapani, University of Milan, milan, Italy

Presentation numberPS4-01-14

Evaluation of Metabolic Dysregulation, Endocrine Therapy Outcomes, and Tumor Biology in HER2-/HR+ Breast Cancer using a Multi-Omic, Real-World Analysis

Jasmin Hundal, Cleveland Clinic, Cleveland, OH

Presentation numberPS4-01-15

Acute and Early Circulating Tumor DNA Dynamics in Metastatic Triple-Negative Breast Cancer Targeted Therapy Phase Ib/II Clinical Trials

Briana To, The Ohio State University Comprehensive Cancer Center, Columbus, OH

Presentation numberPS4-01-16

The transcriptomic profile of circulating T lymphocytes is associated with response to neoadjuvant therapy in patients with early breast cancer

Benedetta Conte, Università del Piemonte Orientale, Novara, Italy

Presentation numberPS4-01-17

Accelerating Access to Precision Medicine in Nigeria through Patient Engagement and Educational Materials

Runcie CW Chidebe, Project PINK BLUE – Health & Psychological Trust Centre, Abuja, Nigeria

Presentation numberPS4-01-18

Prognostic Role of CXCR6 and RANKL for Bone Metastasis in Early Breast Cancer

Hanbaek Yi, Seoul National University Hospital, Seoul, Korea, Republic of

Presentation numberPS4-01-19

Isoform level RNA detection provides more detailed profiling of HER2 expression in breast cancer

Yuanyuan Cheng, Wobble Genomics Ltd, Edinburgh, United Kingdom

Presentation numberPS4-01-20

Clinico-pathological and genomic features of HER2-low early Breast Cancer (eBC). Results of retrospective analysis of seven adjuvant trials by the Hellenic Cooperative Oncology Group (HeCOG)

Sotirios Lakis, Hellenic Cooperative Oncology Group (HeCOG), Athens, Greece

Presentation numberPS4-01-21

Genomic characterization and genetic testing gaps in early-onset breast cancer in Colombia

Maria Alejandra Bravo, Fundación Centro de Tratamiento e Investigación sobre Cáncer(CTIC), Bogota, Colombia

Presentation numberPS4-01-22

The Utility of MT1-MMP in Predicting Treatment Efficacy with HER2-positive advanced or metastatic breast cancer: JBCRG-M06/EMERALD trial TR

Mio Yasukawa, Kanagawa Cancer Center, Kanagawa, Japan

Presentation numberPS4-01-23

Transcriptomic Profiling and Immune-metabolic Prediction Model Construction for Neoadjuvant Chemotherapy Response in Triple-Negative Breast Cancer Patients

Shuning Ding, Shanghai General Hospital,Shanghai Jiao Tong University School of Medicine, Shanghai, China

Presentation numberPS4-01-24

Cytokine score based on expression levels of multiple cytokines is a prognostic indicator in metastatic breast cancer patients treated with chemotherapy

Junko Tsuchida, Hyogo Medical University, Nishinomiya, Hyogo, Japan

Presentation numberPS4-01-25

Noninvasive Early Detection of Breast Cancer via Copy Number Variation Profiling of Nipple Discharge DNA

Wen Wen, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China

Presentation numberPS4-01-26

Development and Validation of TROP2/HER2-low/Ki67/HR multiplex-immunofluorescence panel with membrane identification: enabling improved Antibody Drug Conjugate therapy selection

Yuting Liu, Akoya Biosciences, Marlborough, MA

Presentation numberPS4-01-27

Lower Penetrance Germline Fanconi Anemia Variants in Breast Cancer: Opportunities for Expanded Genetic Testing and Therapeutic Targeting in the Updated INSPIRE Study Cohort

Leah Naghi, City of Hope, Duarte, CA

Presentation numberPS4-01-28

Utility of MSK-ACCESS powered with SOPHiA DDM decentralized testing in patients with breast cancer.

Florian Klemm, SOPHiA GENETICS, Rolle, Switzerland

Presentation numberPS4-01-29

Tumor-derived ZAG expression is associated with immunologically cold tumors and poor response to neoadjuvant chemotherapy in TNBC

Toru Hanamura, Tokai University School of Medicine, Isehara, Japan

Presentation numberPS4-01-30

Identification and characterization of distinct chemoimmunomodulatory states in breast cancer via unsupervised transcriptomic analysis of pre- and post-treatment specimens

Mohammed O. Gbadamosi, University of Florida, Gainesville, FL

Presentation numberPS4-02-01

Differential early response to neoadjuvant endocrine therapy in lobular versus non-lobular breast cancer on the Endocrine Optimization Pilot (EOP) of the I-SPY2 Trial

Rita Mukhtar, University of California, San Francisco, San Francisco, CA

Presentation numberPS4-02-02

Ultrasensitive ctDNA-based MRD monitoring predicts relapse in postoperative HR+ inflammatory breast cancer

Ranjan Upadhyay, MD Anderson Cancer Center, Houston, TX

Presentation numberPS4-02-03

Tumor-educated platelet RNA captures treatment-induced transcriptomic changes and predicts response in luminal breast cancer.

IZASKUN URDANIBIA, IRB LLEIDA, LLEIDA, Spain

Presentation numberPS4-02-04

Revealing the prognostic significance of dephosphorylation-related genes in breast cancer: comprehensive insightsbased on bulk RNAsequencingand single-cell RNA sequencingdata

Chen Wei, Shengli Clinical Medical College of Fujian Medical University, Fuzhou, China

Presentation numberPS4-02-06

Analysis of BRCA1 and 2 mutations as predictive biomarkers of response to trastuzumab deruxtecan in hormone receptor-positive, HER2-low metastatic breast cancer: a systematic review and meta-analysis

Lucas Pivetta Genovez, A. C. Camargo Cancer Center, São Paulo, Brazil

Presentation numberPS4-02-07

A novel serum protein-based assay for monitoring response to therapy and recurrence of breast cancer.

Christine Chavany, Milagen, Inc., Emeryville, CA

Presentation numberPS4-02-08

Circulating tumor cell (CTC) transcriptional profiling identifies diverse CTC phenotypes in metastatic breast cancer.

Viridiana Carreno, University of Wisconsin, Madison, Madison, WI

Presentation numberPS4-02-09

Symptom Clustering and Multi-Omics Signatures of Cancer-Related Fatigue in Breast Cancer: Findings from the China PERSEVERE Cohort

Zheng Qu, University of Pennsylvania, PHILADELPHIA, PA

Presentation numberPS4-02-10

Agreement of cell-free DNA methylation-based molecular breast subtyping and tissue subtyping in hormone receptor positive metastatic breast cancer: a clinical cohort analysis

Letizia Pontolillo, Weill Cornell Medicine, New York, NY

Presentation numberPS4-02-11

Molecular and prognostic profiling of HR+/HER2+ Metastatic Breast Cancer (MBC): insights from circulating tumor DNA (ctDNA)-based genomic analysis

Lorenzo Foffano, University of Udine, Udine, Italy

Presentation numberPS4-02-12

Combination of CDK4/6 and EZH2 Inhibitors Enhances Anti-Tumor Immunity in Triple-Negative Breast Cancer via the MAVS-TBK1-STAT1 Signaling Pathway and Synergizes with Anti-PD-1 Therapy

Sisi Li, Chongqing University Cancer Hospital, Chongqing, China

Presentation numberPS4-02-13

Genes from epithelial-mesenchymal transition predict overall survival effectively in breast cancer:anovel risk model based on initial step of tumor metastasis

Wei-xian Chen, Changzhou No.2 People's Hospital, the Third Affiliated Hospital of Nanjing Medical University, Changzhou, China

Presentation numberPS4-02-14

Recognition of immunogenomic signature and prognostic value of the subtype of epithelial-mesenchymal transition in breast cancer

Wei-xian Chen, Changzhou No.2 People's Hospital, the Third Affiliated Hospital of Nanjing Medical University, Changzhou, China

Presentation numberPS4-02-15

Sumo e3 ligase ranbp2 affects triple-negative breast cancer tumorigenicity by stabilizing birc5 expression

Yuxiang Lin, Fujian Medical University Union Hospital, Fuzhou, China

Presentation numberPS4-02-16

Stress-induced adrenergic signaling promotes endocrine resistance in ER-positive breast cancer

Gilberto Gastelum Martinez, Lombardi Comprehensive Cancer Center Georgetown University, Washington, DC

Presentation numberPS4-02-17

From Metabolites to Mechanisms: Linking Tryptophan Metabolism and AhR Activation in Breast Cancer

Yanming Wu, SUNY Downstate Health Sciences University, Brooklyn, NY

Presentation numberPS4-02-18

Detection of germline and somatic pathogenic variants in patients with de novo metastatic breast cancer (dnMBC) and assessment of their prognostic relevance: A Hellenic Cooperative Oncology Group (HeCOG) translational cohort study

Elena Fountzilas, Hellenic Cooperative Oncology Group (HeCOG), Athens, Greece

Presentation numberPS4-02-19

Mutations in PIK3R1 Activate Multiple Pathways in Triple Negative Breast Cancer

Abde Abukhdeir, Rush University, Chicago, IL

Presentation numberPS4-02-20

Clinical and genomic biomarkers of capivasertib response in patients with hormone receptor-positive, HER2-negative metastatic breast cancer (HR+/HER2- MBC)

Maxwell R Lloyd, Beth Israel Deaconess Medical Center, Boston, MA

Presentation numberPS4-02-21

Prognostic Significance of HER2 Heterogeneity in Early-stage and Locally advanced HER2-positive Breast Cancer

Takaaki Hatano, Osaka University, Suita-city, Japan

Presentation numberPS4-02-22

Dynamics of the Intratumoral Microbiome Across Malignant Transformation and Treatment in Breast Cancer

liuliu quan, cancer hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China

Presentation numberPS4-02-23

Biomarkers of response and resistance to Sacituzumab Govitecan in HR+/HER2− advanced breast cancer: interim results from the phase II SOLTI ACROSS-TROP2 Trial

Eva Ciruelos, University Hospital 12 De Octubre / Instituto de Investigacion Sanitaria Hospital 12 de Octubre (imas12) / SOLTI Cancer Research Group, Madrid, Spain

Presentation numberPS4-02-24

Identifying Prognostic Epithelial-Mesenchymal Transition and Tumor Stem Cell Markers in Breast Cancer Subtypes

Vanessa Dybal Bertoni, Gonçalo Moniz Institute, Oswaldo Cruz Foundation (IGM-FIOCRUZ/BA, Brazil), Salvador, Brazil

Presentation numberPS4-02-25

Single Institution experience of longitudinal post-surgical circulating tumor DNA monitoring in patients with HER2+ breast cancer

Minhal Zaidi, Houston Methodist Neal Cancer Center, Houston, TX

Presentation numberPS4-02-26

Gper signaling as a biomarker for endocrine therapy sensitivity in pik3ca mutant hr+ advanced breast cancer

Tenghua Yu, Jiangxi Cancer Hospital & Institute, Nanchang, China

Presentation numberPS4-02-27

Machine learning-enhanced ultra-deep sequencing for low-abundance circulating tumor DNA (ctDNA) in breast cancer

Yuwei Ni, Burning Rock Biotech, Shanghai, China

Presentation numberPS4-02-28

Outcomes in Metastatic Young Women Breast Cancer under the Personalized Onco-Genomics Program in British Columbia.

Zahi Mitri, BC Cancer Vancouver, Vancouver, BC, Canada

Presentation numberPS4-02-29

Development of an ultra-sensitive droplet digital PCR test for monitoring ESR1 variants in liquid biopsies

Leisa Jackson, Biodesix Inc., Louisville, CO

Presentation numberPS4-02-30

Scoping Review of Biologic and Imaging Markers Associated with Aromatase Inhibitor Related Musculoskeletal Symptoms

Stephanie Rosenberg, University of New Mexico, Albuquerque, NM

Presentation numberPS4-03-01

Tumorsphere Formation as a Liquid Biopsy Biomarker of Tumor Aggressiveness and Metastatic Burden in Breast

Monika Pizon, Laboratory Pachmann, Bayreuth, Germany

Presentation numberPS4-03-03

Age-driven genomic differences in breast cancer: relevance for PI3K-pathway

Nerea Lopetegui-Lia, The Ohio State University, Columbus, OH

Presentation numberPS4-03-04

Hmgcs2 promotes malignant phenotype and apatinib resistance in her2-negative breast cancer via the rab23/β-catenin/tcf signaling axis

Jing Wu, Chongqing University Cancer Hospital, Chongqing, China

Presentation numberPS4-03-06

Aberrant KIF11 induction is a potential driver of aggressiveness in ER-a positive positive breast cancer

Seungpil Jung, Korea University Hospital, Seoul, Korea, Republic of

Presentation numberPS4-03-07

Association of clinical BRCA testing with multigene assay results

Seungji Lee, International St. mary's hospital, Incheon, Korea, Republic of

Presentation numberPS4-03-08

The role of platelets in masking circulating tumor cells

Monika Pizon, Laboratory Pachmann, Bayreuth, Germany

Presentation numberPS4-03-09

Positron emission tomography imaging detected enhanced anti-tumor immunity in triple-negative breast cancer mediated by glutamine antagonism

Hoon Choi, University of Pennsylvania, Philadelphia, PA

Presentation numberPS4-03-10

Assessing the impact of real-time serial circulating tumor cell results on the management of patients with metastatic breast cancer

Karthik V Giridhar, Mayo Clinic, Rochester, MN

Presentation numberPS4-03-11

Uncovering ctDNA-detected co-mutational patterns in HR+/HER2− metastatic breast cancer to inform treatment sequencing

Konstantinos Venetis, European Institute of Oncology IRCCS, Milan, Italy

Presentation numberPS4-03-12

Quantifyher (trial in progress): quantitative immunofluorescence and/or messenger rna to measure her2 expression in patients with metastatic breast cancer treated with trastuzumab deruxtecan (tbcrc066)

Eleanor Plaut Taranto, University of Pennsylvania, Philadelphia, PA

Presentation numberPS4-03-13

Septin9 isoforms predict taxane efficacy in triple negative breast cancer

Jycole Bush, UT Health Science Center San Antonio, San Antonio, TX

Presentation numberPS4-03-15

Repurposing eliglustat as an anti-cancer agent for triple-negative breast cancer

Johannes Francois F Fahrmann, UTMDACC, Houston, TX

Presentation numberPS4-03-16

Characterization of the cytokine profile of metastatic Breast Cancer, from mediators of chronic inflammation to potential biomarkers

Maria M Caffarel, Biogipuzkoa Health Research Institute, Donostia / San Sebastian, Spain

Presentation numberPS4-03-17

Circulating Tumor DNA (ctDNA) Monitoring of High-Risk Breast Cancer Patients: A Retrospective Descriptive Analysis in a Community Setting

Milana V Dolezal, Stanford University School of Medicine, Stanford, CA

Presentation numberPS4-03-18

Homologous Recombination Deficiency and DNA-Damage Response in Breast Invasive Lobular Carcinoma

Christopher J Schwartz, Memorial Sloan Kettering Cancer Center, New York City, NY

Presentation numberPS4-03-19

Machine learning based inference of real-time HER2 activity from gene expression profiling in breast cancer to inform HER2 targeted therapy selection

Saumya D. Sisoudiya, Foundation Medicine Inc., Cambridge, MA

Presentation numberPS4-03-20

Spatial and biomarker associations of CD83, a promising CAR-T target for breast cancer

Maia Homsi, Roswell Park Comprehensive Cancer Center, Buffalo, NY

Presentation numberPS4-03-21

Neoadjuvant chemotherapy impacts her2 status as defined by sataloff classification and consequent follow up in a lower middle-income country

RIM BOUCHELAGHEM, Anticancer Center Annaba, Annaba, Algeria

Presentation numberPS4-03-22

High throughput analysis in locally advanced triple negative breast cancer TNBC: pathological complete response pCR and mutational status.

Ida Paris, Fondazione Policlinico Agostino Gemelli IRCCS, Rome, Italy

Presentation numberPS4-03-23

Detection of Treatment-Resistant ESR1 Mutations by Ultra-sensitive SuperRCA Technology

Duy Nguyen, Quest Diagnostics, San Juan Capistrano, CA

Presentation numberPS4-03-24

Association of HER2 0 vs HER2 low with median OS in patients with breast cancer and BRCA1, BRCA2, and PALB2 pathogenic mutations.

Darya Kizub, MD Anderson Cancer Center, Houston, TX

Presentation numberPS4-03-25

Targeting Pro-Metastatic Stress Kinase Networks in Triple-Negative Breast Cancer Using Patient-Derived Models

Margarite Matossian, University of Chicago, Chicago, IL

Presentation numberPS4-03-26

Cell-free DNA BRCA copy number loss and/or deletions in patients with metastatic breast cancer: incidence and association with clinical and genomic features

Neelima Vidula, Massachusetts General Hospital, Harvard Medical School, Boston, MA

Presentation numberPS4-03-27

M2 Macrophages Predict Response to Neoadjuvant Chemotherapy in Triple Negative Breast Cancer Patients

Wei-xian Chen, Changzhou No.2 People's Hospital, the Third Affiliated Hospital of Nanjing Medical University, Changzhou, China

Presentation numberPS4-03-28

Hypoxia and lactate metabolism-relatedgene signature for prognosis prediction in triple negative breast cancerand hub gene COL5A3 promotes cancer progressionvia PI3K/AKT pathway

Wei-xian Chen, Changzhou No.2 People's Hospital, the Third Affiliated Hospital of Nanjing Medical University, Changzhou, China

Presentation numberPS4-03-29

N-nose as a non-invasive biomarker for predicting neoadjuvant chemotherapy response in breast cancer patients

Akira Nakakami, Gifu university Hospital, Gifu, Japan

Presentation numberPS4-03-30

Desmoplakin, DSP, is a potential tumour suppressive protein in human breast cancer

Hong Yu Xiang, Cardiff University, CARDIFF, United Kingdom

Presentation numberPS4-05-01

Postpartum Associated Breast Cancer and Its Survival Impact among Young Women.

Benjamin Walbaum, Hospital Clinic Barcelona, Barcelona, Spain

Presentation numberPS4-05-03

Pro-c3 as a circulating biomarker of tumor fibrosis in breast cancer: functional insights from studying cancer associated fibroblasts in vitro

Marco Pannone, Nordic Bioscience, Herlev, Denmark

Presentation numberPS4-05-05

EGFR amplification and PI3K pathway mutations identify a subset of breast cancers that synergistically respond to EGFR and PI3K inhibition

Stan Lipkowitz, Center for Cancer Research, NCI, NIH, Bethesda, MD

Presentation numberPS4-05-06

Comparative Analysis of PIK3CA, AKT1, and PTEN Reporting Across Commercial NGS Tests in Breast Cancer (BC)

Hope Rugo, City of Hope, Duarte, CA

Presentation numberPS4-05-07

Integrated Genomic Profiling Identifies Predictive Biomarkers for Neoadjuvant Therapy Response in Chinese Breast Cancers

Zhonghua Wang, Fudan University Shanghai Cancer Center, Shanghai, China

Presentation numberPS4-05-08

Perineural invasion increases the risk of lymph node metastasis in early-stage operable breast cancer:a large-scale propensity-matched cohort study and meta-analysis

Weifeng Cai, Fujian Medical University Union Hospital, Fuzhou, China

Presentation numberPS4-05-10

Plasma neurofilament light chain levels are prognostic in patients with primary breast cancer and are associated with CTC.

Michal Mego, Faculty of Medicine, Comenius University, National Cancer Institute, Bratislava, Slovakia

Presentation numberPS4-05-11

Breast Cancer Drives Detectable Reprogramming in White Blood Cells and Platelets

OLESYA A KHARENKO, Syantra Inc, Calgary, AB, Canada

Presentation numberPS4-05-12

Region-specific collagen morphometric parameters in HER2+ breast cancer versus TNBC: insights from SHG/TPE and AI-based analysis

Kutbuddin Akbary, HistoIndex, Singapore, Singapore

Presentation numberPS4-05-13

Germline microRNA-based variants and lymph node burden in breast cancer

Joanne Weidhaas, UCLA, Los Angeles, CA

Presentation numberPS4-05-14

Integrated NGS-Based Tissue and Plasma Profiling to Advance Precision Oncology in Breast Cancer

Dimitrios Mavroudis, University General Hospital of Heraklion, Heraklion, Greece

Presentation numberPS4-05-15

Immunohistochemical characterization of the tumor cells present in four body fluids from patients with metastatic breast cancer in the context of the UPTIDER program

Camille Carette, KU Leuven, Leuven, Belgium

Presentation numberPS4-05-16

Multi-omics analysis identifies EFR3B as a driver of chemoresistance in breast cancer through epithelial-endothelial cell communication

Yilong Lin, the First Affiliated Hospital of Xiamen University, School of Medicine, Xiamen University, Xiamen, China

Presentation numberPS4-05-18

The predictive value of tumor-to-gland density ratio in pathological complete response to Neoadjuvant chemotherapy in breast cancer

Xiaoyun Mao, The First Affiliated Hospital of China Medical University, Shenyang, China

Presentation numberPS4-05-19

Enumeration of circulating tumor cell (CTC) clusters as a function of age or neutrophil -to-lymphocyte-ratio (NLR) in women with metastatic breast cancer

Marcus Vetter, Cantonal Hospital Baselland, Liestal, Switzerland

Presentation numberPS4-05-20

Genomic Diversity of Breast Carcinomas Exhibiting Biomarker Triads Derived from Quantified Levels of ER, PR and HER2 Proteins or from Expression of Their Cognate Genes

Michael W Daniels, University of Louisville, Louisville, KY

Presentation numberPS4-05-21

The Molecular and Immune Landscape of HER2 Positive Breast Cancer

Yuan Gao, Houston Methodist Hospital, Houston, TX

Presentation numberPS4-05-22

Eprs1 induces ac⁴c modification of mRNAs encoding pluripotency factors in breast cancer cells

Jeetendra K Nag, Cleveland Clinic Research, Cleveland Clinic, Cleveland, OH

Presentation numberPS4-05-23

Investigating Interferon Pathway Biomarkers as Predictors of Disease Free Survival in Triple Negative Breast Cancer

Kathleen Yuan, Washington University in St. Louis, Saint Louis, MO

Presentation numberPS4-05-24

Development of a Novel Platelet RNA Based Biomarkers for Breast Cancer Detection

Jong-Ho Cheun, SMG-SNU Boramae Medical Center, Seoul, Korea, Republic of

Presentation numberPS4-05-26

Classivus: a clinical platform for reclassifying uncertain variants in hereditary breast and ovarian cancer in a Brazilian cohort

Elisângela Paula Silveira-Lacerda, Federal University of Goiás, Goiânia, Brazil

Presentation numberPS4-05-27

Longitudinal multi-omic profiling of tissues and blood to track the molecular evolution of metastatic breast cancer

Henry Kaplan, Swedish Cancer Institute and Paul G Allen Research Center, Seattle, WA

Presentation numberPS4-05-28

Impact of Neoadjuvant Endocrine Therapy on MammaPrint Index in Hormone Receptor-Positive, HER2-Negative MammaPrint Low Risk Early-Stage Breast Cancer

Saya Jacob, University of Pennsylvania, Philadelphia, PA

Presentation numberPS4-05-29

Homologous Recombination Deficiency in Breast Cancer: Exploratory Analysis of a Brazilian Cohort with Germline Genetic Testing.

Andreza Karine de Barros Almeida Souto, Oncoclínicas&Co, Brasília, Brazil

Presentation numberPS4-05-30

Maged1 inhibition enhances sensitivity to parp inhibitors in brca-mutated breast cancer cells

Lee In Hee, Kyungpook National Chilgok University Hospital, Daegu, Korea, Republic of

Presentation numberPS4-04-01

A 15-Gene Predictive Signature for Pathologic Complete Response in Triple-Negative Breast Cancer: Validation Across Institutional and TCGA Cohorts

Chi-Wen Luo, Kaohsiung Medical University Hospital, Kaohsiung city, Taiwan

Presentation numberPS4-04-02

Improving HER2 Status Assessment in Breast Cancer with MammaTyper®: Focus on Equivocal Cases

ANA VELASCO, IRB LLEIDA, LLEIDA, Spain

Presentation numberPS4-04-03

Analytical concordance of NGS-based tests for ESR1 mutation detection in plasma

Ana Vivancos, Vall d'Hebron Institute of Oncology, Barcelona, Spain

Presentation numberPS4-04-04

High RICTOR / Low RPTOR Gene‐Expression Signature as a Predictive Biomarker for Intravenous Everolimus Nanoparticle (Sapu003): Rationale for the First‐in‐Human Trial

Cynthia Lee, Sapu Bioscience, LLC, San Diego, CA

Presentation numberPS4-04-05

Construction and validation of a clinical model predicting pathological complete response after neoadjuvant immunotherapy in breast cancer

Min Lin, Sun Yat-sen University Cancer Center, Guangzhou, China

Presentation numberPS4-04-06

Tumor-on-chip as a personalized platform for rapid drug testing in breast cancer

Clara Helal, Department of Medical Oncology, Institut Curie-Institut of Women’Cancers, Paris, France

Presentation numberPS4-04-07

Improved Diagnostic Accuracy for Breast Implant Rupture Through Strain Elastography – Results of a User-Based Evaluation Using Standardized Image Sets

Hanna Fritsch, St. Franziskus Hospital Münster, Münster, Germany

Presentation numberPS4-04-08

Radioimmunotherapy using ^64/67Copper labelled trastuzumab in mice bearing HER2-positve xenografts as a model for breast cancer therapy

Erica Sztangret, Clarity Pharmaceuticals, Eveleigh, Australia

Presentation numberPS4-04-09

Activity of capivasertib in a panel of ER+ breast XPDX models harboring PI3-K/Akt pathway and other known mutations

Christopher Nelson, The START Center for Cancer Research, San Antonio, TX

Presentation numberPS4-04-10

Preclinical Evaluation of ⁶⁴Cu-Labeled Cetuximab Immuno-PET for Detecting Sentinel Lymph Node Metastasis and Assessing Therapeutic Potential in EGFR-Positive Breast Cancer

Takeshi Usui, The University of Osaka, Suita, Japan

Presentation numberPS4-04-11

Statins enhance trastuzumab deruxtecan efficacy: Preclinical synergy in HER2-negative models and clinical benefit in HER2-positive metastatic breast cancer

Taha Koray Sahin, Hacettepe University, Ankara, Turkey

Presentation numberPS4-04-12

Adaptive selection of p53 mutation metaplastic phenotypes in estrogen-independent progression of ER+ tumors: A mechanism for acquired resistance to hormonal therapy.

Alexander D Borowsky, UC DAVIS, SACRAMENTO, CA

Presentation numberPS4-04-13

Murine models for triple-negative breast cancer with differential responsiveness to immunotherapy

Thomas John Kalantzakos, UT Health San Antonio, San Antonio, TX

Presentation numberPS4-04-14

Evaluation of TNBC-PDX Models for Personalized Medicine

Shotaro Inoue, Kobe University Graduate School of Medicine, kobe, Japan

Presentation numberPS4-04-15

Mechanomedicine targeting of MT1-MMP in TNBC spheroids

Jaemoon Yang, Yonsei University, Seoul, Korea, Republic of

Presentation numberPS4-04-16

Discovering potential drug targets for estrogen receptor-positive breast cancer through Mendelian randomization

Chen Wei, Shengli Clinical Medical College of Fujian Medical University, Fuzhou, China

Presentation numberPS4-04-17

Rpn13pru targeting small molecules induce mitotic arrest in breast cancer.

Santwana K C, National Institute of Health, Bethesda, MD

Presentation numberPS4-04-18

Direct targeting of amplified HER2 gene activates immune signaling through DNA damage response

Adam Krysztofiak, Yale School of Medicine, New Haven, CT

Presentation numberPS4-04-19

A nucleic acid sensing system for selective therapeutic protein expression in breast cancer

Alinés Lebrón-Torres, Broad Institute of MIT & Harvard, Cambridge, MA

Presentation numberPS4-04-20

Ralbp1 depletion downregulates DNA repair and potentiates PARP inhibitor activity in BRCA wild type and mutated breast cancer cell lines

Chhanda Bose, TTUHSC, Lubbock, TX

Presentation numberPS4-04-21

Deciparticle™ Everolimus (Sapu003): From Cytostasis to Cytotoxicity via a Single mPEG Polymer and Clinic-Ready Manufacturing

Sheng-Hao Min, Sapu Bioscience, LLC, San Diego, CA

Presentation numberPS4-04-22

Bacterial-tumor antigen cross reactive T-cells are enriched in tumors of newly diagnosed breast cancer patients.

Denise Cecil, University of Washington Medicine, Seattle, WA

Presentation numberPS4-04-23

Pelp1 inhibition disrupts dna repair and enhances topoisomerase inhibitor efficacy in triple negative breast cancer

Khaled Mohamed Nassar, UT Health SanAntonio, SAN ANTONIO, TX

Presentation numberPS4-04-24

Pharmacological Repurposing of Natural Products for Triple-Negative Breast Cancer

Marelly A Perez, University of the Incarnate Word, San Antonio, TX

Presentation numberPS4-04-25

Selective Cytotoxicity of Natural Products in Triple-Negative Breast Cancer Mediated by PKCβ Activation

Sofia C Stanfield, University of the Incarnate Word, San Antonio, TX

Presentation numberPS4-04-26

Anti-tumor activity of ATNM-400, a first-in-class Actinium-225 antibody radioconjugate, in tamoxifen and trastuzumab resistant breast cancer models

Adeela Kamal, Actinium Pharmaceuticals, New York, NY

Presentation numberPS4-04-27

Slc39a7/zip7as a tumor-specific antigen enabling precision immunotherapy in breast and prostate cancers

John S Manavalan, Cancer Antibodies Inc, Longwood, FL

Presentation numberPS4-04-28

Multifunctional lipid nanoparticles remodeling tumor immune microenvironment for breast cancer chemio-immunotherapy

Huiying Fang, Chongqing University Cancer Hospital, Chongqing, China

Presentation numberPS4-04-29

Antibody Inhibiting SCUBE3 for the Treatment of Triple Negative Breast Cancer

Deepika Singh, Greehey Children's Cancer Research Institute, San Antonio, TX

Presentation numberPS4-04-30

Discovery of NKT5097: a first-in-class, highly potent and selective, orally bioavailable CDK2/4 dual degrader for cancer therapy

Ke Liu, NiKang Therapeutics Inc, Wilmington, DE

Presentation numberPS4-06-02

Combinatory treatments of VRN101099 with antibody therapies for HER2-driven breast cancer

Hong-Ryul Jung, Voronoi Inc, Incheon, Korea, Republic of

Presentation numberPS4-06-04

First-in-human Phase 1 study of BTX-9341, a CDK4/6 bifunctional degrader, as monotherapy and in combination with fulvestrant in patients with advanced and/or metastatic HR+/HER2- breast cancer – first emerging data

Amita Patnaik, The START Center for Cancer Research, San Antonio, TX

Presentation numberPS4-06-05

Sapu003: Everolimus for Injection — Pharmacokinetic Rationale for Phase I Evaluation in HR⁺/HER2⁻ Metastatic Breast Cancer

Wen-Han Chang, Sapu Bioscience, LLC, San Diego, CA

Presentation numberPS4-06-06

Tfx06 dose expansion study showed favorable safety and efficacy in patients with er⁺ /her2^– breast cancer in a phase 2 study

Charles Z Ding, Yangli Pharmaceutical Technology, Hangzhou, China

Presentation numberPS4-06-07

Yes/src kinase inhibitor nxp900, currently in clinical development, combines synergistically with fulvestrant against luminal a breast cancer cell lines in vitro and in vivo

Asier Unciti-Broceta, University of Edinburgh, Edinburgh, United Kingdom

Presentation numberPS4-06-08

A phase 1/2, first-in-human study of AVZO-021, a selective cyclin-dependent kinase 2 inhibitor (CDK2i), as a monotherapy and in combination for patients with advanced solid tumors, including hormone receptor-positive (HR+)/human epidermal growth factor receptor 2-negative (HER2-) breast cancer and cyclin E1 (CCNE1)‑amplified solid tumors: preliminary safety and efficacy results

Alberto J Montero, University Hospitals/Seidman Cancer Center, Case Western Reserve University, Cleveland, OH

Presentation numberPS4-06-09

Efficacy of a novel BCL-xL degrader, DT2216, in the treatment of triple-negative breast cancer

Yuxiang Lin, Baylor College of Medicine, Houston, TX

Presentation numberPS4-06-10

A Promising Approach for Hard-to-Treat Breast Cancer: Photodynamic Therapy with ClAlPc Nanoemulsion Against Triple-Negative Cells

Elisângella de Paula Silveira Lacerda, Federal University of Goiás, Goiânia, Brazil

Presentation numberPS4-06-11

Initial Results from Correlative Analysis of a Single Arm Phase 2 Study of Peri-Operative Immune Checkpoint Inhibition and Cryoablation in Women with Hormone Receptor-Negative, HER2-Negative Early Stage/Resectable Breast Cancer

Shaan Bhandari, UT Southwestern Medical Center, Dallas, TX

Presentation numberPS4-06-12

Dual-payload TROP2 targeted antibody drug conjugate: Multi-Payload Conjugates™ deliver orthogonal mechanisms of cell killing

Marco Lobba, CatenaBio, Berkeley, CA

Presentation numberPS4-06-13

Pharmacokinetic Evaluation of MBQ-167 a Dual Rac/Cdc42 Inhibitor in Advanced Breast Cancer Patients

Jose F Rodriguez-Orengo, MBQ Pharma, Inc., San Juan, PR

Presentation numberPS4-06-14

Tinengotinib in advanced or metastatic HR+/HER2- and TNBC: efficacy and biomarker correlative analysis from a phase Ib/II study

Sarina Piha-Paul, MD Anderson Cancer Center, Houston, TX

Presentation numberPS4-06-15

Safety Run-In Phase of the ATRiBRAVE trial: a Phase II Study Evaluating Ceralasertib Priming Followed by Durvalumab/Nab-Paclitaxel to Restore Immunotherapy Sensitivity in Advanced Triple Negative Breast Cancer (TNBC)

Valentina Guarneri, Oncology 2, Istituto Oncologico Veneto IRCCS, Padova, Italy

Presentation numberPS4-06-17

First clinical data of DB-1310 (HER3-targeted antibody-drug-conjugate), in patients with pretreated hormone receptor-positive/HER2-negative breast cancer: efficacy and safety data from a phase 1/2a trial

Hua Mu, Dualitybiologics, Shanghai, China

Presentation numberPS4-06-18

Early Results from a Phase 1 Clinical Study of a Cancer Vaccine Targeting Tumor Associated Antigen MUC1 in Ductal Carcinoma in Situ for Immune Interception of Breast Cancer

Emilia J Diego, University of Pittsburgh, Pittsburgh, PA

Presentation numberPS4-06-19

Final results of a Phase I trial of an alpha-lactalbumin (aLA) vaccine for breast cancer

Justin M Johnson, Cleveland Clinic, Cleveland, OH

Presentation numberPS4-07-01

Exploring the Impact of Circadian Timing and TIL Status on Immunotherapy Response in Breast Cancer

Kaho Nakamura, Mie University Hospital, Tsu, Japan

Presentation numberPS4-07-02

Determinants of early and late relapse in patients with early triple negative breast cancer from the prospective CANTO Cohort

Chiara Benvenuti, Gustave Roussy, Villejuif, France

Presentation numberPS4-07-03

Adverse Events in Neoadjuvant Therapy for Triple-Negative Breast Cancer: A Systematic Review and Meta-Analysis of Phase III Trials

Marcelo Antonini, Hospital do Servidor Publico Estadual de São Paulo, São Paulo, Brazil

Presentation numberPS4-07-04

Rare but Resistant: Neoadjuvant Chemoimmunotherapy in Special Histological Subtypes of Triple-Negative Breast Cancer — Insights from the Neo-Real/GBECAM-0123 Study

Romualdo Barroso-Sousa, Brasilia Hospital, Oncologia Américas, Brasilia, Brazil

Presentation numberPS4-07-05

JNK1 and JNK2 isoforms promote triple-negative breast cancer aggressiveness by fostering an M2 macrophage-driven immunosuppressive tumor microenvironment

Xuemei Xie, University of Hawaii Cancer Center, Honolulu, HI

Presentation numberPS4-07-06

Independent validation of TNBCDX, a 15-gene genomic risk stratification tool for early-stage triple-negative breast cancer

Fara Braso-Maristany, Fundació de Recerca Clínic Barcelona, Barcelona, Spain

Presentation numberPS4-07-07

Factors associated with pCR and distant recurrence in patients with early-stage TNBC treated with KN522

Rachel Jaber Chehayeb, Hospital of the University of Pennsylvania, Philadelphia, PA

Presentation numberPS4-07-08

Spatial transcriptomics of TNBCs show an association between HOXB13 expression and formation of a plasmablast-rich neighborhood

Blake Flood, Massachusetts General Brigham, Boston, MA

Presentation numberPS4-07-09

Can high TILs compensate for incomplete neoadjuvant pembrolizumab in early TNBC? Insights from the PETRHA cohort

Daniela Vazquez-Juarez, Hospital Zambrano Hellion TecSalud, Tecnologico de Monterrey, San Pedro Garza Garcia, Mexico

Presentation numberPS4-07-10

The Relationship Between Tumor-Infiltrating Lymphocytes (TILs), Pathologic Complete Response, and Event-Free Survival in Patients with Early-Stage Triple-Negative Breast Cancer Treated with KEYNOTE-522 regimen in a Real-World Scenario

Renata Colombo Bonadio, Instituto D'Or de Pesquisa e Ensino (IDOR), São Paulo, Brazil

Presentation numberPS4-07-11

Analysis of patients with triple-negative breast cancer and germline BRCA mutation undergoing neoadjuvant treatment following the keynote 522 protocol in real-world. Insights from the Neo-Real/GBECAM-0123 Study

Monique C Tavares, AC Camargo, SAO PAULO, Brazil

Presentation numberPS4-07-12

Real-world comparison of pembrolizumab dosing schedules (q3w vs q6w) in early TNBC: Insights from the PETRHA cohort

Alejandro Aranda-Gutierrez, Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán, Mexico City, Mexico

Presentation numberPS4-07-13

Safety and Efficacy of Immune Checkpoint Inhibitors in Early Triple Negative Breast Cancer: A Systematic Review and Meta-Analysis of Real-World Evidence vs. Clinical Trial Data

Alessandra Longobardi, University of Naples "Federico II", Naples, Italy

Presentation numberPS4-07-14

Germline BRCA Mutations and Chemo-Immunotherapy Predict Pathologic Complete Response in Triple-Negative Breast Cancer: Insights from a Resource-Limited Setting

Tamer Al-Batsh, King Hussein Cancer Center, Amman, Jordan

Presentation numberPS4-07-15

A single preoperative pembrolizumab dose plus a single subablative radiotherapy fraction (7 Gy) elicits anti-tumor immune response and increases stromal tumor infiltrating lymphocytes in triple negative breast cancer: a phase 1b/2 study

Julia Tchou, University of Pennsylvania, Philadelphia, PA

Presentation numberPS4-07-16

Epigenetic Reactivation of estrogen receptor beta Enhances Antitumor Activity of a Novel estrogen receptor beta agonist CIDD-0149897 in Triple-Negative Breast Cancer

Uday Pratap, UT Health San Antonio, San Antonio, TX

Presentation numberPS4-07-17

Results of the Dose-Expansion Cohort of a Phase 1 Trial of Intratumoral HER2- and HER3-Primed Dendritic Cells Injections for the Treatment of Early-Stage TNBC and HR Low Positive Breast Cancer.DecipHER trial

Ricardo Costa, H. Lee Moffitt Cancer Center, New Tampa, FL

Presentation numberPS4-07-18

Association of tumor-infiltrating lymphocytes (TILs) with outcomes in patients with early TNBC treated with neoadjuvant chemotherapy with or without pembrolizumab

Richard S Lee, Dana-Farber Cancer Institute, Boston, MA

Presentation numberPS4-07-19

An agonist of mitochondrial CLPP, ONC206, overcomes mitochondrial dependencies and abates chemoresistance in triple negative breast cancer

Lily M Baek, Baylor college of medicine, Houston, TX

Presentation numberPS4-07-20

Mitomycin C plus carboplatin followed by paclitaxel vs. standard doxorubicin-cyclophosphamide followed by paclitaxel-carboplatin neoadjuvant therapy in BRCA1/2-associated breast cancer

Petr Vladimirovich Krivorotko, NMRC of Oncology named after N.N.Petrov of MoH of Russia, Saint Petersburg, Russian Federation

Presentation numberPS4-07-21

Safety and Clinical Outcomes of Pembrolizumab Standard Dosing Versus Extended-Interval Dosing in Patients with Breast Cancer

Alexis LeVee, UCLA David Geffen School of Medicine, Los Angeles, CA

Presentation numberPS4-07-22

Chemotherapy Decision Making and Outcomes in Very Early-Stage Triple Negative Breast Cancer

Elyse R. Lopez, MD Anderson Cancer Center, Houston, TX

Presentation numberPS4-07-23

Predictive Markers for Pathological Complete Response to Neoadjuvant Therapy in Early-Stage Triple-Negative Breast Cancer: A Single-Center Study in Vietnam.

Anh DINH, Vietnam National Cancer Hospital, Hanoi, Viet Nam

Presentation numberPS4-07-24

Phase 3 study of neoadjuvant pembrolizumab plus chemotherapy followed by adjuvant pembrolizumab for early-stage TNBC: KEYNOTE-522 magnetic resonance imaging (MRI) subgroup analysis

Javier Cortés, Quironsalud Group, and IOB Madrid, Hospital Beata Maria Ana, and Universidad Europea de Madrid, Faculty of Biomedical and Health Sciences, Department of Medicine, Madrid, Spain

Presentation numberPS4-07-25

Real World Analysis of Efficacy, Toxicity, and Treatment Patterns of Pembrolizumab-Containing Regimens for Older Adults with Early-Stage Triple Negative Breast Cancer

Claire Smith, Dana Farber Cancer Institute, Boston, MA

Presentation numberPS4-07-26

Safety and efficacy of neoadjuvant cyclophosphamide, methotrexate, fluorouracil (CMF) and pembrolizumab in older adults with early triple negative breast cancer (TNBC)

Rima Patel, Icahn School of Medicine at Mount Sinai, New York, NY

Presentation numberPS4-07-27

Pembrolizumab + chemotherapy vs placebo + chemotherapy as neoadjuvant treatment, followed by pembrolizumab vs placebo as adjuvant treatment for early-stage TNBC: a post hoc analysis of participants included and separately of those not included in the first interim analysis for pCR in the KEYNOTE-522 study

Peter Schmid, Queen Mary University London, Charterhouse Square, London EC1M 6BQ, United Kingdom

Presentation numberPS4-07-29

Evaluating the tolerability of the combination of adjuvant pembrolizumab and capecitabine in a diverse real-world cohort of patients with early-stage TNBC

Prathyusha Pandu, Mount Sinai West, New York, NY

Presentation numberPS4-07-30

A Phase II Trial of Ivonescimab in Combination with Carboplatin and Docetaxel in Patients with Early Stage Triple Negative Breast Cancer (TNBC)

Yuan Yuan, Cedars-Sinai Medical Center, Los Angeles, CA

Presentation numberPS4-10-01

Neoadjuvant immune checkpoint inhibitors plus chemotherapy in early-stage triple-negative breast cancer: A systematic review and meta-analysis.

Emmanouil Saloustros, University Hospital of Larissa, Larissa, Greece

Presentation numberPS4-10-02

A Real-World Correlation Analysis on the Age at Diagnosis, Pathologic Complete Response, Germline Mutations, and Toxicity in Early Triple-Negative Breast Cancer Patients Treated with the Neoadjuvant Therapy KEYNOTE-522

Stephanie Adel Haddad, UT Health San Antonio/Mays Cancer Center, San Antonio, TX

Presentation numberPS4-10-03

Programmed cell death ligand 1 (PD-L1) expression profiles of early-stage triple-negative breast cancer (TNBC) in China: a retrospective observational study

Jiali Wang, MSD China, Shanghai, China

Presentation numberPS4-10-04

Her2 expression is associated with pathologic complete response to neoadjuvant chemo-immunotherapy among patients with stage 1-3 triple negative breast cancer

Jennifer L Baker, UCLA, santa monica, CA

Presentation numberPS4-10-06

Analysis of Adverse Events and Outcomes of Adjuvant Therapies in TNBC as Monotherapy and Combination: Pembrolizumab, Capecitabine, and Olaparib

Rodolfo Garza-Morales, Mayo Clinic Arizona, Phoenix, AZ

Presentation numberPS4-10-07

Pathologic complete response rates in early-stage triple negative metaplastic breast cancer in the neoadjuvant immunotherapy era: a retrospective review

Naomi Dempsey, Miami Cancer Institute, Miami, FL

Presentation numberPS4-10-08

Impact of BRCA Mutation Status on Pathologic Complete Response and Treatment Patterns in Triple-Negative Breast Cancer Patients Treated with Chemoimmunotherapy: A Real-World Analysis

Mohammad F ALDAWOUD, King Fahad Medical City, Riyadh, Saudi Arabia

Presentation numberPS4-10-09

A cell-free DNA prognostic indicator for pathological response and recurrence in early triple negative breast cancer

Sabine Kasimir-Bauer, University Hospital Essen, Essen, Germany

Presentation numberPS4-10-10

Trends in Neoadjuvant Pembrolizumab Use in Triple Negative Breast Cancer

Ellen Li, Cornell University, Ithaca, NY

Presentation numberPS4-10-11

Pre and Post Treatment Microbiota Profiling in Archival Tumour Tissue fromEarly-Stage Triple-Negative Breast Cancer

Emilene da Silva Morais, University College Cork, Cork, Ireland

Presentation numberPS4-10-12

Real-world efficacy of non-anthracycline neoadjuvant chemo-immunotherapy in early-stage triple negative breast cancer: a retrospective two site cohort study

Amanda K Mennie, UNIV TX SW MEDICAL CTR, Dallas, TX

Presentation numberPS4-10-13

Clinical Feasibility and Reproducibility of Tumor Infiltrating Lymphocyte (TIL) Reporting for Early-Stage Triple Negative Breast Cancer Patients at the University of Washington

Lynn Symonds, Fred Hutch Cancer Center, Seattle, WA

Presentation numberPS4-10-14

Prognostic and Predictive Role of Neutrophil-to-Lymphocyte and Platelet-to-Lymphocyte Ratios in Triple-Negative Early Breast Cancer Treated with Neoadjuvant Chemoimmunotherapy

Ana Godoy-Ortiz, Medical Oncology Unit.,Virgen de la Victoria University Hospital, Malaga, Spain

Presentation numberPS4-10-16

Tumor Immune Microenvironment as a Predictive Marker of Neoadjuvant Pembrolizumab Combined with Chemotherapy (KEYNOTE-522 Regimen) Efficacy in Early Triple-Negative Breast Cancer

Nami Yamashita, Cancer Institute Hospital of JFCR, Koto-ku, Japan

Presentation numberPS4-10-17

The Impact of Pre-Treatment Clinical, Pathological, and Radiological Parameters on Pathological Complete Response and Prognosis Following Neoadjuvant Therapy in Patients with Triple-Negative Breast Cancer

Perya Abbasoglu, Istanbul Medipol University, Istanbul, Turkey

Presentation numberPS4-10-18

Tils as a predictor of response in triple-negative breast cancer: analysis of clinical and pathological outcomes in patients undergoing neoadjuvant chemotherapy based on the keynote-522 protocol in a brazilian cancer center

FLAVIA BALINT, Ac Camargo Cancer Center, Sao Paulo, Brazil

Presentation numberPS4-10-19

Impact of Adjuvant Capecitabine in Triple Negative Breast Cancer Patients Undergoing Perioperative Pembrolizumab: A Real-World Brazilian Cohort.

Marcela O Sá, Materdei, Belo Horizonte, Brazil

Presentation numberPS4-10-20

Exploring Potential Predictive Factors for Immunotherapy Response in Early-Stage TNBC: Insights from a Retrospective Analysis

Aroob Sweidan, Henry Ford Hospital, Detroit, MI

Presentation numberPS4-10-21

Clinicopathological Features and Outcomes of Apocrine Triple-Negative Breast Cancer: A Distinct Subtype with Favorable Prognosis

Thamilyn Saruwatari, AC camargo Cancer Center, São Paulo, Brazil

Presentation numberPS4-10-22

Obesity and Triple Negative Breast Cancer: Untangling the Connection

Brusi Kola, Mitchell Cancer Institute, Mobile, AL

Presentation numberPS4-10-23

Uncovering Mechanisms Driving Phenotypic Distinctions between Breast Cancer Cells with Different p53 Mutations using a 3D Microfluidic Platform

Lydia Sakala, Arizona State University, Tempe, AZ

Presentation numberPS4-10-24

Longitudinal trends in prognosis and post-treatment pregnancy in young woman with triple-negative breast cancer

Mikiko Kasahara, Cancer Institute Hospital of Japanese Foundation for Cancer Research, Tokyo, Japan

Presentation numberPS4-10-25

Intralesional Injection of IL-2 Prior to Surgery in Early-Stage Triple Negative Breast Cancer

Gregory Knapp, Dalhousie University, Halifax, NS, Canada

Presentation numberPS4-10-27

Tolerability of the KEYNOTE-522 regimen in a diverse real-world cohort of patients with early triple negative breast cancer (TNBC)

Justine Anderson, Icahn School of Medicine at Mount Sinai, New York, NY

Presentation numberPS4-10-28

Neoadjuvant Chemoimmunotherapy in Early-Stage TNBC: Real-World Analysis of Predictors of pCR and Survival

Ahmet Bilici, Istanbul Medipol University, Medical Faculty, Istanbul, Turkey

Presentation numberPS4-10-29

Diverse adjuvant treatment in triple-negative breast cancer patients with residual disease after neoadjuvant chemotherapy: A single center real-world study

Xi Chen, Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, beijing, China

Presentation numberPS4-10-30

Evaluating real world pathologic complete response (pCR) rates at an urban center following the KEYNOTE-522 regimen for early-stage TNBC

Justine Anderson, Icahn School of Medicine at Mount Sinai, New York, NY

Presentation numberPS4-08-01

Overall Survival and Breast Cancer-Specific Survival in HER2-Low versus HER2-Zero Breast Cancer: A Single-Center Cohort Study

Min Jung Lee, National Cancer Center, Goyang, Korea, Republic of

Presentation numberPS4-08-02

Prognosis and Management of DCIS with Microinvasion: Insights from SEER Database and a Chinese Cohort

Yaping Yang, sun yat-sen memorial hospital, Guangzhou, China

Presentation numberPS4-08-03

An Exploratory Clinical Study for Neoadjuvant Treatment of HER2-low Expressing, Stage II-III Breast Cancer with Vedolizumab in Combination with Pembrolizumab

Ting Luo, West China Hospital, Sichuan University, China, Chengdu, China

Presentation numberPS4-08-04

Impact of adjuvant chemotherapy in the survival outcomes of early-stage hormone receptor (HR)-positive HER2-negative lobular versus ductal carcinoma patients

Arya Mariam Roy, The Ohio State University, Columbus, OH

Presentation numberPS4-08-05

Evaluating Idiopathic Granulomatous Mastitis Using the Inflammatory Breast Cancer Scoring System: A Comparative Study Highlighting the Role of Pain as a Diagnostic Criterion

Jacqueline Tsai, Stanford University, Stanford, CA

Presentation numberPS4-08-06

Optimizing Postoperative Adjuvant Therapy for Early-Stage Breast Cancer by Combining Dynamic ctDNA MRD Monitoring with Clinical Risk Stratification: An Open-label, Multicenter, Prospective Study (AMENDER)

Fei Ma, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China

Presentation numberPS4-08-07

Predicting response and survival after neoadjuvant systemic treatment with on-treatment biopsies

Carsten Denkert, Philipps-University Marburg and University Hospital Marburg (UKGM), Marburg, Germany

Presentation numberPS4-08-08

Comparison of localization techniques for non-palpable breast cancer: real world data

Kristin Lupinacci, University of Pittsburgh Medical Center, Pittsburgh, PA

Presentation numberPS4-08-09

Long-term outcomes and prognostic factors in metaplastic breast cancer treated with curative intent: a 22-year multicenter retrospective cohort study

Sze Wa Shirley Tse, Queen Elizabeth Hospital, Hong Kong, Hong Kong

Presentation numberPS4-08-10

Clinical characteristics and survival outcomes of Pleomorphic Lobular Carcinoma: a comparative analysis with classical ILC and IDC

David Walji, University of Toronto, Toronto, ON, Canada

Presentation numberPS4-08-11

Standardized Definitions for Efficacy End Points (STEEP, STEEP2) in the CCTG MA.32 randomized breast cancer trial of metformin versus placebo: Implications of the type of recurrence and new non-breast cancer primary on outcome assessment

Katarzyna Joanna Jerzak, University of Toronto, Toronto, ON, Canada

Presentation numberPS4-08-12

Adherence to Fasting Diet and Mediterranean Diet protocol in women with early stage breast cancer receiving chemotherapy; a randomized clinical trial

Dimitrios Tryfonopoulos, St Savas Oncology Hospital, Athens, Greece

Presentation numberPS4-08-13

The intrinsic subtypes in a large cohort of pure DCIS – frequencies and associations with local recurrence

Michael T Hallett, Western University, London, ON, Canada

Presentation numberPS4-08-14

A Systematic Review and Extracted Individual Patient Data Meta-analysis of Long- Term Outcomes in Triple-Negative Breast Cancer after a Pathologic Complete Response: Does the Type of Neoadjuvant Therapy Matter?

Lis Victoria Ravani, University of Sao Paulo School of Medicine, São Paulo, Brazil

Presentation numberPS4-08-15

Towards Personalized Medicine – Patient-Derived Breast Tumor Grafts as Predictors of Relapse and Response to Therapy: Final Results

Christos Vaklavas, Huntsman Cancer Institute, Salt Lake City, UT

Presentation numberPS4-08-16

Evaluation of Clinicopathological Features and Prognoses of Male Patients with Breast Lymphoma

Abdulmunir Azizy, Istanbul University Institute of Oncology, Istanbul, Turkey

Presentation numberPS4-08-17

Evaluation of Clinicopathological Features and Prognoses of Female Breast Sarcoma Patients

Abdulmunir Azizy, Istanbul University Institute of Oncology, Istanbul, Turkey

Presentation numberPS4-08-18

Tailoring escalated adjuvant chemotherapy for multifocal and multicentric breast cancer with low tumor burden

Yizi Zheng, The First Affiliated Hospital of Wenzhou Medical University, Wenzhou, China

Presentation numberPS4-08-19

Different gene expression between breast cancer and adjacent normal breast tissue according to breast cancer subtype

Ji Yeon Kim, Samsung Medical Center, Seoul, Korea, Republic of

Presentation numberPS4-08-20

Immune-related adverse events and pathological complete response in early TNBC treated with neoadjuvant chemo-immunotherapy: a real-world analysis

Gonzalo Lendinez-Sanchez, Hospital Regional Universitario de Málaga, Málaga, Spain

Presentation numberPS4-08-21

Neoadjuvant breast cancer in a real life experience in Southern of Italy

Mariangela Ciccarese, Regional Agency for Social and Health development, Bari, Italy

Presentation numberPS4-08-22

Hypofractionated Whole Breast Irradiation with Concomitant Boost following Breast Conservation Surgery in Early-Stage Breast Cancer.

Pavnesh Kumar, The Ohio State University Wexner Medical Center, Columbus, OH

Presentation numberPS4-08-23

Reassessing Systemic Therapy in Breast Adenoid Cystic Carcinoma: Insights from a Large Retrospective Cohort

Alexandra Bili Newman, MD Anderson Cancer Center, Houston, TX

Presentation numberPS4-08-24

The Mechanisms and Predictors of Aromatase Inhibitor-associated MusculoSkeletal Symptoms: The ZAP Trial 

Jennifer Sheng, Johns Hopkins University, baltimore, MD

Presentation numberPS4-08-25

Trends and determinants of non-treatment in early-stage breast cancer (ESBC)

Marija Sullivan, The University of Texas MD Anderson Cancer Center, Houston, TX

Presentation numberPS4-08-26

Weekly carboplatin and paclitaxel with trastuzumab and pertuzumab (HER2+) or bevacizumab (HER2-) in the neoadjuvant treatment of breast cancer: a phase II trial

Farah Shah, University of California Irvine, Orange, CA

Presentation numberPS4-08-27

Risk of CNS relapse following pathological complete response to neoadjuvant chemotherapy

Luciana de Moura Leite, AC Camargo Cancer Center, Sao Paulo, Brazil

Presentation numberPS4-08-28

Patient-reported outcomes of adjuvant therapy with CDK4/6 inhibitors for HR+/HER2- early breast cancer: a retrospective cohort study

Yongsheng Wang, Tumor Hospital Affiliated to Shandong First Medical University, Jinan, China

Presentation numberPS4-08-29

Neoadjuvant antibody-drug conjugates for early-stage breast cancer: a systematic review and meta-analysis

Gabriela Barbosa Silva, Oncoclínicas&CO, Rio de Janeiro, Brazil

Presentation numberPS4-08-30

Prognostic evaluation of HER2-low status in patients with early breast cancer who underwent neoadjuvant chemotherapy

Sofia Giusti Alves, Hospital de Clínicas de Porto Alegre, Porto Alegre, Brazil

Presentation numberPS4-11-01

Medicare Part B Drug Cost Burden of Pembrolizumab Based Triple Negative and Dual HER2 Triple Positive Regimens for Early Breast Cancer at 2025 Q3 Payment Rates.

Pragya Jain, Baptist Hospital of Southeast Texas, Beaumont, TX

Presentation numberPS4-11-02

Factors associated with lymph node metastasis and its prognostic impact in breast cancer patients with small tumors (≤2cm)

Janghee Lee, Ewha Womans University Mokdong Hospital, Seoul, Korea, Republic of

Presentation numberPS4-11-03

Prognostic impact of PET and/or breast MRI radiological response in early breast cancer patients undergoing neoadjuvant chemotherapy

Matilde Corianò, University Hospital of Parma, Medical Oncology and Breast Unit, Parma, Italy

Presentation numberPS4-11-04

Impact of contemporary neoadjuvant regimens in young women with early breast cancer: A real world temporal analysis from a Brazilian cancer center

Larissa Rodrigues Garcia, AC Camargo Cancer Center, São Paulo, Brazil

Presentation numberPS4-11-05

Usefulness of axillary ultrasonography in selecting cases in which sentinel node biopsy can be omitted for early breast cancer

Wakako Tajiri, NHO Kyushu Cancer Center, Fukuoka, Japan

Presentation numberPS4-11-06

A comparison of mortality in SOUND matched population – A single institution experience

Chandana Gavisiddappa, University Hospitals of Morecambe Bay NHS Foundation Trust, Lancaster, United Kingdom

Presentation numberPS4-11-07

Residual axillary disease in Node-Positive Breast Cancer Patients After Neoadjuvant systemic therapy- A Single centre Retrospective Study

Qurratulain A Chougle, Guy's & St Thomas NHS Trust, London, United Kingdom

Presentation numberPS4-11-08

Clinical characteristics and prognosis in interval detected breast cancer patients: a single institution cohort analysis

Yesim Eralp, Acibadem MAA University, Research Institute of Senology, Maslak Acibadem Hospital, Istanbul, Turkey

Presentation numberPS4-11-09

Axillary Management Strategies in Breast Cancer Patients With ypN0 After Neoadjuvant Therapy

Qingyao Shang, National Cancer Center/Cancer Hospital, Chinese Academy of Medical Sciences, Beijing, China

Presentation numberPS4-11-10

Patient-centric development of shared decision-making aids: The ASSESS online personalized early breast cancer treatment decision support tool and resource website

Bethany A Kerr, Susan G. Komen, Dallas, TX

Presentation numberPS4-11-11

Germline Mutation Landscape in DCIS: Impact of Age and Family History in a Middle Eastern Cohort

Sarah Abdel-Razeq, King Hussein Cancer Center, Amman, Jordan

Presentation numberPS4-11-12

Impact of the ESMO-MCBS v2.0 on Benefit-Risk Assessment of Emerging Therapies in Early Breast Cancer: A Comparison with the ASCO Value Framework

Vittoria Molinaro, University of Naples "Federico II", Naples, Italy

Presentation numberPS4-11-13

Psychosocial determinants in patients with early breast cancer undergoing neoadjuvant therapy: initial results from a prospective study

Yael Bar, Tel Aviv Medical Center and The Faculty of Medicine, Tel Aviv University, Tel Aviv-Yafo, Israel

Presentation numberPS4-09-01

Listening to the Community: Barriers and Beliefs About Clinical Trials Among Black Women with Breast Cancer

Sabrina Mayhew, QLHC, San Francisco, MI

Presentation numberPS4-09-02

Mortality trends in Mexico: Epidemiological Analysis from 83 444 cases

Claudia H Arce-Salinas, Instituto Nacional de Cancerologia, CDMX, Mexico

Presentation numberPS4-09-03

Impact of comorbidities and race in breast cancer survival across cancer stages

Matthew Sanborn, Lankenau Medical Center, Wynnewood, PA

Presentation numberPS4-09-04

Global disparities in breast cancer clinical trials and their impact on clinical evidence, driven by underrepresentation of low- and middle-income countries.

Varsha Gupta, Roswell Park Comprehensive Cancer Center, Buffalo, NY

Presentation numberPS4-09-06

Retrospective evaluation of neutropenia and Duffy-Null Associated Neutrophil Counts (DANC) among breast cancer patients receiving chemotherapy

Bhawneet Chadha, Montefiore Einstein Comprehensive Cancer Center, Bronx, NY

Presentation numberPS4-09-07

Insurance Status as a significant contributor of disparities in outcomes among young breast cancer patients- A retrospective analysis from National Inpatient Sample

Vaishali Deenadayalan, Roswell Park Comprehensive Cancer Center, Buffalo, NY

Presentation numberPS4-09-08

Expanding Diversity through Innovation: Development of the I-SPY ACCESS Initiative for the I-SPY2.2 and DCIS RECAST Clinical Trials

Sara L Horton, Quantum Leap Healthcare Collaborative, San Francisco, CA

Presentation numberPS4-09-09

Distinct Immune and Metabolic profiles in Latin American breast cancer patients with obesity enrolled in FLEX

Marcela Mazo Canola, Mays Cancer Center, UT Health San Antonio, MD Anderson Cancer Center, San Antonio, TX

Presentation numberPS4-09-10

Geographic Barriers are Key Predictors of Clinical Trial Enrollment in Breast Cancer: A National Cancer Database Analysis

Ana Sandoval-Leon, Miami Cancer Institute, Miami, FL

Presentation numberPS4-09-11

Associations of patient-reported social determinants of health (SDOH) with treatment deferral and clinic no-show rates in a diverse population of patients with breast cancer

Emily L Podany, Washington University in St. Louis, St. Louis, MO

Presentation numberPS4-09-12

Adverse Social Determinants of Health Are Associated With Lower Rates of Cardiotoxicity Surveillance in Trastuzumab-Treated Breast Cancer Patients

Divya Samat, Tower Health-Reading Hospital, Reading, PA

Presentation numberPS4-09-13

Elevated Genomic Risk and Treatment Gaps in Black Patients with HR+ Early Breast Cancer: A MammaPrint-Based Retrospective Analysis

Srishti Sareen, University of Tennesse, Memphis, TN

Presentation numberPS4-09-14

Timing delays from diagnosis to first treatment in black and hispanic versus white women with triple-negative breast cancer

Marcela Mazo Canola, UT Health San Antonio, San Antonio, TX

Presentation numberPS4-09-15

More than a number: Does the NCCN Distress Score Capture Key Social Determinants of Health Risks in Patients with Breast Cancer?

Amanda Golden, Washington University in St. Louis, St. Louis, MO

Presentation numberPS4-09-16

Role of surgeon discussions in post-mastectomy reconstruction racial disparities

Faith Dickerson, University of Wisconsin School of Medicine and Public Health, Madison, WI

Presentation numberPS4-09-17

Breast Cancer in Transgender Patients Following Medical and Surgical Intervention

Ayush Thakur, Case Western Reserve University School of Medicine, Cleveland, OH

Presentation numberPS4-09-18

Factors with Immunotherapy Use Among Patients with Triple Negative Breast Cancer in California: A Population-Based Study

Jackelyn Moya, UCSF, San Francisco, CA

Presentation numberPS4-09-19

Factors influencing time to treatment initiation for breast cancer in Ethiopia

Anteneh A Kibret, La Trobe University, Melbourne, Australia

Presentation numberPS4-09-20

Trends and Disparities in Mortality Among U.S. Females with Breast Cancer and Hypertensive Diseases, 1999-2023

Abat Khan, Memorial Healthcare System, Pembroke Pines, FL

Presentation numberPS4-09-21

Disparities in Breast Cancer Mortality Among Individuals with Mental and Behavioral Disorders: A 25-year population-Based Analysis

Anas Al-Zubaidi, The University of Texas Medical Branch, Galveston, TX

Presentation numberPS4-09-22

Uneven Progress: A Two-Decade Analysis of Regional Variations in Breast Cancer Mortality in the United States.

Anas Al-Zubaidi, The University of Texas Medical Branch in Galveston, Galveston, TX

Presentation numberPS4-09-23

Palliative Care Utilization and Associated Outcomes in Hospitalized Breast Cancer Patients: Using The National Inpatient Sample 2021

Srinishant Rajarajan, AGH, Pittsburgh, PA

Presentation numberPS4-09-24

Clinical and economic impact of the 21-gene assay for guiding treatment in patients with HR+/HER2- early breast cancer across racial and ethnic subgroups in the US.

Gebra Cuyun Carter, Exact Sciences, Madison, WI

Presentation numberPS4-09-25

Variation in diagnostic imaging features of breast cancer by race and ethnicity

Ashley Odai-Afotey, Dana-Farber Cancer Institute, Boston, MA

Presentation numberPS4-09-26

Implementation of Integrated Mammography and Genetic Evaluation Services (IMAGES) in Underserved Communities

Jacynda Casey, University of Texas MD Anderson Cancer Center, Houston, TX

Presentation numberPS4-09-27

Global inequalities in female breast cancer burden by decomposition and age-period-cohort analysis, 1990-2021

Ke Li, Peking University People's Hospital, Beijing, China

Presentation numberPS4-09-28

Air Pollution and Oncotype DX recurrence socre: implications for racial disparities in breast cancer

Lindsay J Collin, Emory University, Atlanta, GA

Presentation numberPS4-09-29

Variation in weight loss and intervention engagement in the Breast Cancer Weight Loss (BWEL) trial by language and ethnicity (Alliance)

Ashley Odai-Afotey, Dana-Farber Cancer Institute, Boston, MA

Presentation numberPS4-09-30

Mapping Inequity: Racial Variations in Breast Cancer Hospital Admissions and Clinical Outcomes in the U.S.

Tijin Ann Mathew, Southeast Health, Dothan, AL

Presentation numberPS4-11-16

Treatment Delays and Testing Disparities May Contribute to Racial Differences in Node-Positive ER+/HER2- Breast Cancer Outcomes

Lesley Coe, Albert Einstein College of Medicine, Bronx, NY

Presentation numberPS4-11-18

Financial Toxicity in Breast Cancer Patients Assessed by the COST Score: A Systematic Review and Meta-analysis

Natalia Cristina C. Nunes, Brazilian National Cancer Institute – INCA, Rio de Janeiro, Brazil

Presentation numberPS4-11-19

Investigating Genomic and Treatment Heterogeneity in HER2+ and Triple Negative Breast Cancers

Sarah C Van Alsten, University of North Carolina at Chapel Hill, Chapel Hill, NC

Presentation numberPS4-11-20

Comparative Adherence to Adjuvant Hormonal Therapy and Associated Mortality in Male and Female Veterans with Breast Cancer: A Nationwide Cohort Analysis

Sonika Prasad, Saint Louis Univeristy, Saint Louis, MO

Presentation numberPS4-11-21

Breast Cancer Trends and Outcomes Among Young Hispanic and Asian/Pacific Islander Women Age < 40 in the National Cancer Database (NCDB) adjusted for U.S. population data

Poornima Saha, Endeavor Health, Evanston, IL

Presentation numberPS4-11-22

Molecular characteristics of TNBC and pathologic response to chemoimmunotherapy: a focus on racial disparities

Melanie Sheen, Ochsner MD Anderson Cancer Center, New Orleans, LA

Presentation numberPS4-11-23

Correlates of Distance Traveled to Treatment Centers Among Breast Cancer Patients: The Role of Race/Ethnicity and Insurance Status

Diya Desai, Vanderbilt University, Nashville, TN

Presentation numberPS4-11-24

Enhancing Quality of Care Using Project ECHO: Insights from Breast Density and Advanced Breast Cancer Treatment Programs

Allison Rosen, American Cancer Society, Atlanta, GA

Presentation numberPS4-11-25

Evaluating Underrepresentation in Breast Cancer Clinical Trial Enrollment at Yale Cancer Center: A Retrospective Demographic Study

Jessica Liu, Yale School of Medicine, New Haven, CT

Presentation numberPS4-11-26

First latin american consensus on the medical oncology management of early-stage hr+/her2− breast cancer: addressing regional disparities in spanish-speaking countries of central and south america

Denis Ulises Landaverde, Mexico Hospital, San Jose, Costa Rica

Presentation numberPS4-11-27

Acceptability of a web-based narrative video intervention to promote clinical trial decision making among Black women with breast cancer

Ryan Nguyen, University of Illinois Chicago, Chicago, IL

Presentation numberPS4-11-28

Breast Clinical Reporting and Data System (BCRADS): A Pragmatic, Low-Cost Tool for Early Detection of Breast Cancer in LMICs

Soumen Das, Institute of Breast Disease, NCRI Hospital, Kolkata, Kolkata, India

Presentation numberPS4-11-29

Pathological Complete Response and Breast-Conserving Surgery in Patients Undergoing Neoadjuvant Chemotherapy for Breast Cancer in an Institution fully Funded by the Brazilian Public Health System in Bahia, Brazil

Daniela Cristina Camarotti, Hospital Santo Antônio/Obras Sociais Irmã Dulce, Salvador, Brazil

Presentation numberPS4-11-30

A Retrospective Review of Demographics and BMI on ER Positive and Negative Breast Cancer in Rural Southeast Alabama

Namitha Thotli, Southeast Health, Dothan, AL

Presentation numberPS4-12-02

Challenges in Breast Cancer Screening and Awareness in Sierra Leone – Initiatives by Thinking Pink Breast Cancer Foundation and Breast Cancer Hub

Lopamudra Das Roy, Breast Cancer Hub, Concord, NC

Presentation numberPS4-12-03

Access-her: assessing consequences of standard-of-care gaps in her2-positive breast cancer in the brazilian healthcare system

André Mattar, Hospital da Mulher, SÃO PAULO, Brazil

Presentation numberPS4-12-04

Late-stage breast cancer in young appalachian women: missed hereditary risk and persistent disparities in a community health setting

Jasneet Gill, Tennova North Knoxville Medical Center, Powell, TN

Presentation numberPS4-12-05

Real-world evidence of ethnic-racial disparities in tumor-infiltrating lymphocytes and survival outcomes in early-stage triple-negative breast cancer

Jessé Lopes da Silva, Brazilian National Cancer Institute, Rio de Janeiro, Brazil

Presentation numberPS4-12-06

Breast Cancer in Appalachia: A Comprehensive Analysis of Behavioral and Socioeconomic Factors Influencing Stage at Diagnosis

Jasneet Gill, Tennova North Knoxville Medical Center, Powell, TN

Presentation numberPS4-12-07

Correlations between Race and Area Deprivation Index (ADI) on Treatment and Outcomes in Metastatic TNBC

Anumita Chakraborty, University of Pittsburgh Medical Center, Pittsburgh, PA

Presentation numberPS4-12-08

Oncotype DX prediction of recurrence by race

Quinn S Solfisburg, Boston Medical Center, Boston, MA

Presentation numberPS4-12-09

Racial and Ethnic Disparities in Enrollment to Breast Cancer Clinical Trials from 2000 to 2025

Fatma Nihan Akkoc Mustafayev, Miami Cancer Institute, Baptist Health South Florida, Miami, FL

Presentation numberPS4-12-10

A novel therapeutic targeting triple negative breast cancer brain metastases

Hanna Y. Irie, Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, New York, NY

Presentation numberPS4-12-11

Covid-19 and breast cancer disparities: were our fears realized?

Ruvarashe Rumano, The Ohio State University, Columbus, OH

Presentation numberPS4-12-12

Racial Disparities in Pathologic Complete Response in Patients with HER2 Positive Breast Cancer Treated with Neoadjuvant Chemotherapy

Regina Matar-Ujvary, Cleveland Clinic Foundation, Cleveland, OH

Presentation numberPS4-12-13

Real-world comparison of tumor-infiltrating lymphocytes and survival in advanced triple-negative breast cancer across racial groups in brazil

Jessé Lopes da Silva, Brazilian National Cancer Institute, Rio de Janeiro, Brazil

Presentation numberPS4-12-14

Clinicopathological Features of Gestational Breast Cancer in Syria: A Comparative Study

Ayla Kouli, Damascus University Faculty of Medicine, Damascus, Syrian Arab Republic

Presentation numberPS4-12-15

Racial and Ethnic Disparities in Mental Health Care Among Breast Cancer Survivors with Serious Psychological Distress

Ahmed Allibhai, Southlake Hospital, Newmarket, ON, Canada

Presentation numberPS4-12-16

A Transitional Era of Breast Cancer Care after Sanctions Cessation in Syria: Current Challenges and Future Aspirations

Ayla Kouli, Damascus University Faculty of Medicine, Damascus, Syrian Arab Republic

Presentation numberPS4-12-17

Analyzing Mortality Trends and Disparities in Pulmonary Embolism and Breast Cancer among U.S. Patients: A Decade Long Population-Based Retrospective Study, 2010-2020.

Alina Abbas, Mayo Hospital, Lahore, Pakistan

Presentation numberPS4-12-18

Socioeconomic Status and Delayed Breast Cancer Care in Southeast Texas:ARetrospective Cohort Study

Abdullah Jamal, Baptist Hospitals of Southeast Texas, Beaumont, TX

Presentation numberPS4-12-19

Ethnoregional Disparities in Breast Cancer Screening: A National Database Analysis

Shubhank Goyal, University of Texas Rio Grande Valley, McAllen, TX

Presentation numberPS4-12-20

Regional Variation in Guideline Concordance for Women with Triple-Negative and HER2+ Breast Cancer in Nova Scotia

Ashley Drohan, Izaak Walton Killam Health, Halifax, NS, Canada

Presentation numberPS4-11-14

Anthracycline-based Systemic Chemotherapy on Long-term Prognosis of Metaplastic Breast Cancer: A Real World Study with 637 Cases in 14 multi-center

Can Zhou, First Affiliated Hospital of Xi' an Jiaotong University, Xi' an, China

Presentation numberPS4-10-26

Pretreatment neutrophil-to-lymphocyte ratio is associated with pathologic complete response following neoadjuvant chemo-immunotherapy in early triple-negative breast cancer

Alexis LeVee, UCLA David Geffen School of Medicine, Los Angeles, CA

Presentation numberPS4-11-15

Effect of exercise training during neoadjuvant chemotherapy on breast cancer pathological complete response

Ruffo Freitas-Junior, Federal University of Goias, Goiânia, Brazil

Presentation numberPS4-02-05

Patient-derived organoids (PDO) as functional models to capture interindividual heterogeneity in breast cancer chemotherapy response.

Erico Tosoni Costa, Institute of Education and Research of the Hospital Sírio-Libanês (IEP-HSL), Sao Paulo, Brazil

Presentation numberPS4-12-21

Breast Cancer Profile and Healthcare Practices Among Transgender Patients within the Brazilian Unified Health System: a mixed cross-sectional and survey study (TRANSformation)

Giovana Onzi, AstraZeneca, São Paulo, Brazil

Presentation numberPS4-03-02

P-climb: pet-ct and liquid biopsy for monitoring breast cancer bone metastasis

Deloris Veney, The Ohio State University, Columbus, OH

Presentation numberPS4-05-02

Rapid and ultrasensitive detection of surgical margin and metastatic lymph node via EpCAM-targeted surface-enhanced Raman scattering biosensor in breast cancer

Kangliang Lou, School of Medicine, Xiamen University, Xiamen, China

Presentation numberPS4-06-30

Increased Survival in Nude Mice Inoculated with MCF7 Breast Cancer (BC) in the Mammary Fat-Pad Achieved via a Single Injection of a Lipid-like Hydrogel Emulsion Containing a New Molecular Entity (NME) and N-allyl Noroxymorphone (NaN) Compared to Tamoxifen (TAM) and Abemaciclib (ABE)

Bryan S Margulies, Zetagen Therapeutics, Syracuse, NY

Presentation numberPS4-12-22

Uncovering Barriers in Clinical Trials for Cancer Care at a tertiary oncology center – survey feasibility study

Anne-Laure Strong, Penn State College of Medicine, HERSHEY, PA

Presentation numberPS4-06-29

A TROP2-targeting interferon-beta mutein fusion protein overcomes antibody-drug conjugate (ADC) resistance in breast cancer: a translational approach beyond ADCs

Hee Geon Park, R&D Center, ABION Inc, Seoul, Korea, Republic of

Presentation numberPS4-05-04

Evaluation of a 113-gene predictor of benefit from neoadjuvant T-AC treatment in an I-SPY2 cohort

Jacob H Niklassen, Aida Oncology, Copenhagen, Denmark

Presentation numberPS4-05-09

Molecular Profiling of Malignant Effusions in Advanced Breast Cancer via cfDNA and Tumor Cells Analysis: A Complementary Approach to Guide Targeted Therapy

Elba Marín, Pangaea Oncology, Barcelona, Spain

Presentation numberPS4-12-23

Regional variability and healthcare disparities in the management of early-onset breast cancer in Peru

Iris Otoya, Oncología Médica, Instituto Nacional de Enfermedades Neoplásicas, Lima, Peru

Presentation numberPS4-06-28

Initial clinical and pharmacology results from START-002: A phase 1b/2 clinical investigation of invikafusp alfa (STAR0602), a first-in-class dual T cell agonist, in combination with sacituzumab govitecan in patients with mTNBC or HR+/HER2- mBC

Steven J Isakoff, Mass General Cancer Center, Boston, MA

Presentation numberPS4-06-22

Niche-specific clustering of immune-suppressive cell populations and signals in breast cancer bone metastases

Déja Grant, Meharry Medical College, Nashville, TN

Presentation numberPS4-12-24

Risk and Pattern of Relapse in Triple-Negative Breast Cancer with Pathological Complete Response after Neoadjuvant Treatment: Updated Results from the European GAMBIT Real-world Study

Maria Vittoria Dieci, Department of Surgery, Oncology and Gastroenterology (DiSCOG), University of Padova; Oncology 2, Veneto Institute of Oncology IOV IRCCS, Padova, Italy

Presentation numberPS4-12-26

Neosaci-io: neoadjuvant sacituzumab govitecan (sg) + pembrolizumab (pb) in patients (pts) with early-stage tnbc experiencing suboptimal response to keynote-522

Clinton Yam, The University of Texas MD Anderson Cancer Center, Houston, TX

Presentation numberPS4-12-28

A novel approach for phenotyping triple negative breast cancer using an Artificial Intelligence digital pathology-based prognostic test to assess recurrence risk and response to therapy

Michael Donovan, Icahn School of Medicine at Mount Sinai; PreciseDx, Miami, FL

Presentation numberPS4-12-29

Backbone optimization with dose-dense anthracyclines and prophylactic G-CSF improves pCR without added febrile neutropenia in pembrolizumab-treated TNBC: real-world evidence from Latin America

Diego Bustos, FUNDACION ARTURO LOPEZ PEREZ, Santiago, Chile

Presentation numberPS4-12-30

Overall survival and prognostic factors in patients with triple-negative breast cancer treated with adjuvant capecitabine: real-world experience in a peruvian cohort

Miguel Chirito, Instituto Nacional de Enfermedades Neoplasicas, Lima, Peru

Presentation numberPS4-06-01

Targeting eIF4A unleashes type I IFN immunity in triple-negative breast cancer

Na Zhao, Baylor College of Medicine, Houston, TX